In the past few years, an unprecedented number of immunotherapeutic agents such as anti‐PD‐L1, atezolizumab, have been proved the better survival benefit compared with standard chemotherapy in advanced patients with NSCLC, which greatly has expanded treatment selections beyond first‐line treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.